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Abstract
The clinical progression of Gerstmann-
Straussler-Scheinker disease in a family
of Alsatian origin is reported. The age of
onset and the duration of evolution were
variable. The clinical picture became
more complex over the generations: in the
first generations, isolated dementia and in
later generations a triad of pyramidal,
pseudobulbar syndromes and dementia
associated with spinal cord and cerebeilar
features. Prion gene analysis showed that
four surviving patients carry double mis-
sense changes at codons 117 and 129,
identical to those found in one case at
necropsy and 10 other healthy members of
the family. The missense changes were not
found in 100 controls. No member of the
family had modification of condons 102,
178, or 200. The lod score suggests linkage
between the missense change at codon 117
and Gerstmann-Straussler-Scheinker
disease in this family.
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In 1982, Warter et al' reported observations on
a family of Alsatian origin in which at least
eight members presented with Gerstmann-
Straussler-Scheinker (GSS) disease. This
familial disease of autosomal dominant trans-
mission23 can sometimes be transmitted to
laboratory animals via intracerebral inocula-
tion of brain homogenates from GSS patients
whose disease has incubated for periods of
months to years. The infectious agent has not
as yet been indentified, but a protease-resistant
isoform of the prion protein,4" PrP, has been
found in these patients' brains. Molecular
genetic studies have recently detected a poly-
morphism of the PrP gene in GSS families,6 in
particular a missense variant at codon 102
resulting in a substitution of leucine (leu 102)
for proline (pro 102).`-9 Tateishi et al have
reported in one member of the Alsatian family,
a missense PrP variant with an alanine (GCA)
to valine (GTG) change at codon 117 and a
methionine (ATG) to valine (GTG) change at
codon 129 on the same PrP allele. In this case,
the attempts to transmit GSS to animals were
negative.' We summarise here the clinical and
genetic studies in this family (AND family).
Subjects and methods
The family tree includes 76 subjects over six
generations. We have usable clinical and gen-
etic data for 65 (fig).
PrP gene analyses-High molecular weight
DNA was prepared from the frozen brain
tissue of patient IV-28 and from leucocytes of
47 living family members. The PrP coding
region was amplified by the polymerase chain
reaction (PCR) method, and the substitutions
in codons 102, 117, 129, 178, and 200 were
detected by dot-blot hybridisation and PvuII
restriction mapping of the PCR-amplified
DNA.8 The results were compared with those
from 100 control patients: 20 patients from the
same town as the GSS family, half of whom
had Alzheimers' disease, and 80 white subjects
healthy or having other neurological diseases.
Genetic study-The family data were analysed
for genetic linkage with the linkage programs
version 4 7 (R).'° We assumed that the disease
followed a dominant mode of inheritance with
penetrance depending non-linearly on age,
from 0% at age 19 to 100% at 60 and over.
Results
The eight cases previously reported' and four
new cases are summarised in table 1. In three
cases (IV-3, IV-9, and IV-28) a cerebral biopsy
specimen showed numerous multicentric or
unicentric amyloid plaques' which were PrP
positive to immunohistochemical stains,5
axonal degeneration at or surrounding the
plaques, neuronal degeneration, and a moder-
ately intense spongiosis. Patient III-3, mother
of IV-9, and hospitalised at present, began her
illness at 64 years of age, in 1984, with a right
hemiparesis followed by a pseudobulbar syn-
drome, a cerebellar syndrome, dementia, and
an extrapyramidal syndrome. For the last 18
months, the patient has been bedridden and
demented; she now has epileptic seizures.
Patient III-13 died aged 48 years after one
year's progression characterised by a pseudo-
bulbar syndrome, an asymmetrical pyramidal
syndrome, and intellectual deterioration which
in six months led to a bedridden state. There
was no necropsy. Patient IV-25 became ill four
years ago at 33 years of age, starting with an
asymmetrical pyramidal syndrome followed by
extrapyramidal and pseudobulbar syndromes,
a state of dementia, and a cerebellar syndrome.
For the past year he has been bedridden.
Finally, one year ago, at 57 years of age, patient
III-1 1, mother of IV-26 and IV-28, presented
walking difficulties, dysarthria, and intellectual
deterioration. She has been bedridden and
demented for a few weeks.
PrP gene analyses-No member of the family
had either insertion-deletion mutation or sub-
stitutional mutation at codons 102, 178, or
200. Four patients still alive at present carried
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double missense changes at codons 117 and
129 like patient IV-28, as well as 10 healthy
members of the family between 11 and 38
years of age whose condition is not discussed
for reasons of confidentiality. The missense
change at codon 117 was not found in 100
control patients. The missense change at codon
129 was, however, found in the family and the
controls. Of the 100 control subjects, 43 had
the double allele methionine, 40 had alleles
methionine and valine, and 17 had double
allele valine. In the GSS family, the missense
change at codon 1 7 was always associated on
the same allele with the methionine to valine
substitution at the codon 129. This methionine
to valine substitution was carried heterozy-
gously by all the members of the family with
the double missense, except one of the 10
healthy members, who carried it homozygously.
Genetic analysis-According to these data, the
population frequency p for the missense change
at codon 117 was estimated as having a 95%
confidence interval between 0 to 0-015. The 99%
confidence interval for p extends from 0 to 0-023.
As GSS is extremely rare (estimated one to 10
cases per 107) population frequency ofq = 1 per
107 was assumed for the GSS gene. The log
likehood ratio (lod score) varied between
Z = 2-185 at a recombination fraction of = 0,
(p = 1 X i0-7) and Z = 2-023 (recombination
fraction e = 0, p = 0 023). The confidence inter-
val for the recombination fraction 9, approximat-
ed by the lod score value Z-1, ranges from 0 to
0-28 for p = 107 and from 0 to 0-26 for
p = 0-023 (table 2).
Discussion
This family of vinmers and artisans has lived in
Alsace since at least 1795. Patient I-I's direct or
allied ascendants are now being studied. No
conclusion is yet possible. The family disease is
transmitted in the autosomal dominant mode.
There are three sets of clinical signs: dementia
alone in the first generations and, later, dementia
followed by progressive hemiparesis which then
became bilateral and was accompanied by a
pseudobulbar syndrome. In the most recent
generations, there is dementia, a pseudobulbar
syndrome, and the appearance of more complex
neurological signs associating a cerebellar syn-
drome, an extrapyramidal syndrome (fixed faces,
severely stooped posture, and hypertonia), motor
neuron signs with fasciculations and amyotrophy,
spontaneous or provoked myoclonia, and gener-
alised tonic-clonic seizures. The age of onset,
which at first appeared to be limited to the
interval between 30 and 45 years, is in fact much
Table 1 Clinical characteristics offamily members with Gerstmann-Strdussler-Scheinker disease
Disease devel- Pseudo bul-
Family Onset age opment Codon 117 Progressive bar syn- Extra pyramidal Fascicula- Seizures of
member (years) (years) Sex mutation Dementia hemiparesis drome Ataxia syndrome tions myoclonus
I 1 44 3 M NA +
II 2 43 3 F NA +
II 4 40 3 M NA +
III 7 26 5 M NA + + + + +
III 9 43 3 M NA + + +
IV 3 35* 2 M NA + + + + +
IV 9 35* lit F + + + + + + +
IV 28 20* 4 M + + + + + + + +
III 3 64 6t F + + + + + + +
III 13 47 1 F NA + +
IV 25 33 4t M + + + + + +
III I1 56 it F + + +
NA: information not available.
*From biopsy specimen.
tPatient still living.
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Table 2 Lod scores for several values ofp, the valine substitution frequency
P =o0 9=001e =005 e =01 =02 8=0-3
0-023 2-023 2-018 1-962 1-835 1-464 0-980
0-015 2-076 2-071 2-015 1-888 1-514 1-022
10-4 2-184 2-180 2-126 1-998 1-617 1-112
10 ' 2-185 2-181 2-127 1999 1-618 1-112
e recombination fraction.
wider: 20 years at the youngest, 64 at the oldest.
The duration of disease, three to five years in the
first cases, may vary from one year to at least 10
years in the case of one patient still alive. No
correlations could be established between onset
age, sex, symptomatology, and generation. In
several cases the disease started in the children
before their parents (patients IV-28 and IV-25
before r-I 1 and patient IV-9 before IEI-3) and,
among sisters and brothers, the older after the
younger. The histopathological lesions examined
in three patients, on the other hand, are similar.'
The AND family's clinical features lie between
the ataxic form58 1' and the dementing form of
GSS.'2 Experimental transmission of the disease
from patient IV-28 to mice was negative, as
reported previously.5 The negative transmissions
from this patient and other GSS patients contrast
with the almost 100% positivity from sporadic
Creutzfeldt-Jakob disease patients.5 The low
infectivity also contrasts with the high penetrance
of the disease in GSS families such as this one.
The analysis of the PrP gene has shown a
GCA-to-GTG mutation at codon 117. This
missense mutation seems to be specific to this
family; it has never been described in any other
GSS family or any control subject. The loss of the
Pvul restriction site, probably by a silent GCA-
to-GCG transition at the third base of codon 117
apparently represents a normal polymorphism of
the gene which is found in 10% of white
people.'3 The missense mutation at codon 117
reported here is presumably due to a C-to-T
transition at the CpG dinucleotide mutation hot
spot"4 of this GCG sequence at codon 117. The
missense change at codon 129 was carried not
only by the patients but also by over half (57) of
controls, suggesting that it might be a normal
polymorphism of the gene. We have to take into
account, however, that the missense change at
codon 117 was always combined with the change
at codon 129 in this family. The lod score
suggests a correlation between the valine change
at codon 117 and the GSS disease gene in this
family. The value of 2-185 is certainly below the
threshold of the Z = 3 value generally admitted
as significant, but in this extremely rare disease,
there can be difficulties about estimating the
frequency of the PrP variant in the population.
The role of the PrP variant is unclear. InAND
family, it apparently influences neither the dura-
tion of incubation nor the progression of the
disorder, unlike certain polymorphisms in animal
pathology.'17 Contrary to the suggestions of
Baker et al 8 amino-acid polymorphism at codon
129 in the normal allele seems not to influence
these clinical data. It is also too soon to know
whether the codons 117 and 129 variants in this
family or the codon 102 variant in other families
are a predisposing factor or the factor responsible
for the disease.'9 20
Continued clinical observation may give the
answer. Follow up of the families with GSS
patients, and above all of the now healthy carriers
of a mutation of the prion gene, should suggest
the potential role of the prion in the induction of
the disorder. If all the healthy carriers develop
GSS the mutation may be considered to be
sufficient for disease development; if not, it must
be interpreted as necessary but not sufficient.
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